HypotensionNCT07663695
Propofol vs. Ciprofol for Anesthesia Induction in Frail Elderly Patients
A study testing Ciprofol and Propofol in people with Hypotension, run by General Hospital of Ningxia Medical University at 1 site in China.
Trial summary
Post-induction hypotension (PIH) is a common and critical complication during general anesthesia, particularly in frail elderly patients whose physiological reserves are significantly diminished. PIH is strongly associated with adverse postoperative outcomes, including acute kidney injury (AKI) and myocardial injury. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Hypotension
- What is being tested?
- Ciprofol and Propofol
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteChina
- Study dates
- 25 Jun 2026to 31 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients scheduled to undergo major abdominal surgery under general anesthesia.
- Frailty score >= 3[cite: 2].
- Age >= 60 years[cite: 2].
- American Society of Anesthesiologists (ASA) physical status class >= II[cite: 2].
- Planned invasive blood pressure monitoring[cite: 2].
Who cannot join
- Severe cardiac arrhythmia[cite: 2].
- Severe valvular heart disease[cite: 2].
- Poorly controlled hypertension with medication (systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 110 mmHg)[cite: 2].
- Pre-existing preoperative hypotension (mean arterial pressure < 65 mmHg)[cite: 2].
- Preoperative renal dysfunction (serum creatinine greater than the upper limit of normal)[cite: 2].
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750000
General Hospital of Ningxia Medical University, +86-0951-4091488, 13909713260@139.com
About this study
Official title: Comparison of the Effects of Propofol and Ciprofol on the Incidence of Post-induction Hypotension in Frail Elderly Patients Undergoing General Anesthesia
Post-induction hypotension (PIH) is a common and critical complication during general anesthesia, particularly in frail elderly patients whose physiological reserves are significantly diminished. PIH is strongly associated with adverse postoperative outcomes, including acute kidney injury (AKI) and myocardial injury. Propofol is the most widely used induction agent but frequently induces circulatory depression. Ciprofol, a novel anesthetic agent developed by optimizing the molecular structure of propofol, has demonstrated improved hemodynamic stability and fewer adverse effects in general populations. However, its specific impact on frail elderly patients remains unestablished.
The primary purpose of this single-center, randomized, double-blind, controlled trial is to compare the effects of propofol and ciprofol during anesthesia induction on the incidence of PIH in frail elderly patients undergoing major abdominal surgery. The investigator's hypothesis is that ciprofol will significantly lower the incidence of PIH compared to propofol. Additionally, the study will evaluate secondary clinical outcomes, such as postoperative AKI, postoperative cardiac complications, and the overall quality of recovery, to provide an evidence-based clinical guide for selecting optimal induction agents for this vulnerable patient population.
Read the detailed description
Background and Rationale:
Frail elderly patients exhibit an accumulation of multi-system physiological decline, making them highly vulnerable to surgical and anesthetic stressors. During the induction of general anesthesia, these patients are at an exceptionally high risk for severe and prolonged hypotension due to reduced cardiac stroke volume, impaired autonomic nervous system regulation, and altered pharmacokinetics. Post-induction hypotension (PIH)-occurring from the initiation of anesthesia to 10 minutes post-intubation-is directly influenced by the choice of induction agent and the patient's baseline condition, with fewer confounding factors than intraoperative hypotension.
While propofol is highly efficient, its prominent side effect is cardiovascular depression. Ciprofol is an innovative 2,6-disubstituted phenol derivative that maintains the rapid onset and recovery advantages of propofol while offering enhanced hemodynamic stability. To date, clinical evidence comparing these two agents specifically in the frail elderly population is lacking. This study seeks to evaluate whether ciprofol can mitigate the risk of PIH in frail elderly patients undergoing major abdominal surgery and to observe its downstream impacts on major organ protection and postoperative recovery quality.
Study Workflow and Anesthesia Management:
- Patient Screening: Patients aged 60 or older with a frailty score >= 3 undergoing major abdominal surgery under general anesthesia with planned invasive blood pressure monitoring will be screened on the day before surgery.
- Randomization and Blinding: Eligible participants will be randomized in a 1:1 ratio to either the Propofol Group or the Ciprofol Group. Both patients and outcome assessors will be blinded to the group allocation.
- Intervention:
- Propofol Group: Anesthesia induction will be performed using midazolam, sufentanil, propofol, and rocuronium.
- Ciprofol Group: Anesthesia induction will be performed using midazolam, sufentanil, ciprofol, and rocuronium.
- Monitoring and Follow-up: Standardized intraoperative and perioperative management will be applied uniformly across both groups. Hemodynamic parameters will be monitored continuously. Postoperatively, patients will be followed up to evaluate acute kidney injury (AKI) within 48 hours, cardiac complications (including MINS, congestive heart failure, and acute myocardial infarction) within 7 days or during hospitalization, and overall recovery quality metrics (including mechanical ventilation time, PACU and ICU stay duration, and total postoperative hospital stay).
- Conditions
- Hypotension
- Being tested
- Ciprofol, Propofol
- Keywords
- Propofol, Ciprofol, Anesthesia Induction, Frail Elderly
- Medical subject headings
- Hypotension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CiprofolDrug
An innovative 2,6-disubstituted phenol derivative used for general anesthesia induction.
PropofolDrug
An alkylphenol derivative and standard intravenous anesthetic agent used for general anesthesia induction.
| Study group | Role | What they receive |
|---|---|---|
| Ciprofol | Experimental | Frail elderly patients undergoing major abdominal surgery who receive ciprofol for general anesthesia induction, combined with midazolam, sufentanil, and rocuronium. Receives: Drug: Ciprofol |
| Propofol Group | Active comparator | Frail elderly patients undergoing major abdominal surgery who receive propofol for general anesthesia induction, combined with midazolam, sufentanil, and rocuronium. Receives: Drug: Propofol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of post-induction hypotension (PIH)
Post-induction hypotension (PIH) is defined as a mean arterial pressure (MAP) < 65 mmHg lasting for more than 1 minute.
Measured: From the initiation of general anesthesia drug administration until 10 minutes after endotracheal intubation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2026
- Study start25 Jun 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypotensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- General Hospital of Ningxia Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07663695
- Sponsor's protocol ID
- Hongmei Ma
- Status last verified
- Jun 2026
- First submitted
- 17 Jun 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Effects of Propofol and Ciprofol on the Incidence of Post-induction Hypotension in Frail Elderly Patients Undergoing General Anesthesia
- ClinicalTrials.gov ID
- NCT07663695
- Acronym / sponsor ID
- Hongmei Ma
- Conditions
- Hypotension
- Keywords
- Propofol, Ciprofol, Anesthesia Induction, Frail Elderly
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- General Hospital of Ningxia Medical UniversityUniversity, hospital or other
- Study start
- 25 Jun 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Jan 2027 (estimated)
- First posted
- 23 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Post-induction hypotension (PIH) is a common and critical complication during general anesthesia, particularly in frail elderly patients whose physiological reserves are significantly diminished. PIH is strongly associated with adverse postoperative outcomes, including acute kidney injury (AKI) and myocardial injury. Propofol is the most widely used induction agent but frequently induces circulatory depression. Ciprofol, a novel anesthetic agent developed by optimizing the molecular structure of propofol, has demonstrated improved hemodynamic stability and fewer adverse effects in general populations. However, its specific impact on frail elderly patients remains unestablished.
The primary purpose of this single-center, randomized, double-blind, controlled trial is to compare the effects of propofol and ciprofol during anesthesia induction on the incidence of PIH in frail elderly patients undergoing major abdominal surgery. The investigator's hypothesis is that ciprofol will significantly lower the incidence of PIH compared to propofol. Additionally, the study will evaluate secondary clinical outcomes, such as postoperative AKI, postoperative cardiac complications, and the overall quality of recovery, to provide an evidence-based clinical guide for selecting optimal induction agents for this vulnerable patient population.
Detailed description
Background and Rationale:
Frail elderly patients exhibit an accumulation of multi-system physiological decline, making them highly vulnerable to surgical and anesthetic stressors. During the induction of general anesthesia, these patients are at an exceptionally high risk for severe and prolonged hypotension due to reduced cardiac stroke volume, impaired autonomic nervous system regulation, and altered pharmacokinetics. Post-induction hypotension (PIH)-occurring from the initiation of anesthesia to 10 minutes post-intubation-is directly influenced by the choice of induction agent and the patient's baseline condition, with fewer confounding factors than intraoperative hypotension.
While propofol is highly efficient, its prominent side effect is cardiovascular depression. Ciprofol is an innovative 2,6-disubstituted phenol derivative that maintains the rapid onset and recovery advantages of propofol while offering enhanced hemodynamic stability. To date, clinical evidence comparing these two agents specifically in the frail elderly population is lacking. This study seeks to evaluate whether ciprofol can mitigate the risk of PIH in frail elderly patients undergoing major abdominal surgery and to observe its downstream impacts on major organ protection and postoperative recovery quality.
Study Workflow and Anesthesia Management:
- Patient Screening: Patients aged 60 or older with a frailty score >= 3 undergoing major abdominal surgery under general anesthesia with planned invasive blood pressure monitoring will be screened on the day before surgery.
- Randomization and Blinding: Eligible participants will be randomized in a 1:1 ratio to either the Propofol Group or the Ciprofol Group. Both patients and outcome assessors will be blinded to the group allocation.
- Intervention:
- Propofol Group: Anesthesia induction will be performed using midazolam, sufentanil, propofol, and rocuronium.
- Ciprofol Group: Anesthesia induction will be performed using midazolam, sufentanil, ciprofol, and rocuronium.
- Monitoring and Follow-up: Standardized intraoperative and perioperative management will be applied uniformly across both groups. Hemodynamic parameters will be monitored continuously. Postoperatively, patients will be followed up to evaluate acute kidney injury (AKI) within 48 hours, cardiac complications (including MINS, congestive heart failure, and acute myocardial infarction) within 7 days or during hospitalization, and overall recovery quality metrics (including mechanical ventilation time, PACU and ICU stay duration, and total postoperative hospital stay).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ciprofol | Experimental | Drug: CiprofolFrail elderly patients undergoing major abdominal surgery who receive ciprofol for general anesthesia induction, combined with midazolam, sufentanil, and rocuronium. |
| Propofol Group | Active comparator | Drug: PropofolFrail elderly patients undergoing major abdominal surgery who receive propofol for general anesthesia induction, combined with midazolam, sufentanil, and rocuronium. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients scheduled to undergo major abdominal surgery under general anesthesia.
- Frailty score >= 3[cite: 2].
- Age >= 60 years[cite: 2].
- American Society of Anesthesiologists (ASA) physical status class >= II[cite: 2].
- Planned invasive blood pressure monitoring[cite: 2].
Key exclusion criteria (5 listed)
- Severe cardiac arrhythmia[cite: 2].
- Severe valvular heart disease[cite: 2].
- Poorly controlled hypertension with medication (systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 110 mmHg)[cite: 2].
- Pre-existing preoperative hypotension (mean arterial pressure < 65 mmHg)[cite: 2].
- Preoperative renal dysfunction (serum creatinine greater than the upper limit of normal)[cite: 2].
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CiprofolAn innovative 2,6-disubstituted phenol derivative used for general anesthesia induction. | Drug | Ciprofol |
| PropofolAn alkylphenol derivative and standard intravenous anesthetic agent used for general anesthesia induction. | Drug | Propofol Group |
Primary outcome
Incidence of post-induction hypotension (PIH)
Time frame: From the initiation of general anesthesia drug administration until 10 minutes after endotracheal intubation.
Post-induction hypotension (PIH) is defined as a mean arterial pressure (MAP) < 65 mmHg lasting for more than 1 minute.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
Related trials for Hypotension
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
RecruitingPhase 4
Remimazolam Versus Propofol for Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Venous Pressure
Intraoperative Hypotension, Hepatectomy
Not yet recruitingPhase 4
Effect of Ondansetron on the Incidence of Spinal Anaesthesia-Induced Hypotension in Elderly Patients Undergoing Fracture Hip Surgery
Spinal Anaesthesia Induced Hypotension
Not yet recruitingObservational study
Postprandial Hypotension, Frailty and Post-Induction Hypotension in Older Patients Undergoing Noncardiac Surgery
Post-induction Hypotension (PIH), Postprandial Hypotension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ciprofol and Propofol in people with Hypotension, run by General Hospital of Ningxia Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hongmei Ma (+86 13909713260, 13909713260@138.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of post-induction hypotension (PIH) (time frame: From the initiation of general anesthesia drug administration until 10 minutes after endotracheal intubation.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.